Status of accelerated fractionation radiotherapy in head and neck squamous cell carcinomas

Current Opinion in Oncology

Volumn 9, Issue 3, 1997, Pages 262-266

  Bourhis, Jean ^a   Wibault, Pierre ^a   Lusinchi, Antoine ^a   Bobin, Serge ^a   Luboinski, Bernard ^a   Eschwege, François ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CARCINOMA; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR CELL;

EID: 0030845102     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709030-00008     Document Type: Short Survey

References (50)

1. Thomas F, Ozanne F, Mamelle G, Wibault P, Eschwege F: Radiotherapy alone for oropharyngeal carcinoma: the role of fraction size (2 Gy vs 2.5 Gy) on local control and early and late complications. Int J Radiat Oncol Biol Phys 1988, 15:1097-1102.
2. Peters L, Ang K: The role of altered fractionation in head and neck cancer. Semin Radiat Oncol 1992, 2:180-194.
3. Horiot JC, LeFur N, Guyen T, et al.: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC group of radiotherapy. Radiother Oncol 1992, 25:231-241.
4. Keane T, Cummings B, O'Sullivan M, Cummings R: Results of a randomized trial of hyperfractionated versus conventional radiation therapy administered over 4 weeks for squamous carcinoma of the larynx and pharynx. Proceedings of the fourth International Conference on Head and Neck Cancer. Toronto, 1996:92. Preliminary results of a randomized trial which included 336 patients, comparing 51 Gy/20 fractions/28 d to 58 Gy/40 fractions/28 d (hyperfractionated) and suggesting a benefit in terms of improved local control for primary tumors less than 4 cm in size.
5. Pinto L, Canary P, Araujo C, et al.: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stage III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991, 21:557-562.
6. Datta N, Chouldhry A, Gupta S: Twice a day versus once a day radiation therapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989, 17:132.
7. Marcial V, Pajak T, Chang C, et al.: Hyperfractionated radiation therapy in the treatment of head and neck carcinoma: preliminary report of the RTOG. Int J Radiat Oncol Biol Phys 1987, 13:41-47.
8. Sanchiz F, Milla A, Torner J: Single fraction versus two fractions per day versus radiochemotherapy in the treatment of HNSCC. Int J Radiat Oncol Biol Phys 1990, 19:1347-1350.
9. Cox JD, Pajak TF, Marcial V, et al. for the ASTRO Plenary: Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from radiation therapy oncology group protocol 8313. Int J Radiat Oncol Biol Phys 1991, 20:1191-1195
10. Cox J: Clinical perspective of recent developments in fractionation. Semin Radiat Oncol 1992, 2:10-15.
11. Dische S, Saunders M: The rationale for continuous hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 1990, 19:1317-1320.
12. Fowler JF: How worthwhile are short schedules in radiotherapy? a series of exploratory calculations. Radiother Oncol 1990, 18:165-181
13. Fowler J: Rapid repopulation in radiotherapy: debate on mechanism. The phantom of tumor treatment: continually rapid repopulation unmasked. Radiother Oncol 1991, 22:156-158.
14. Withers H, Taylor J, Maciejevski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
15. Thames HD, Peters L, Withers H, Fletcher G: Accelerated fractionation vs hyperfractionation: rationale for several treatments per day. Int J Radiat Oncol Biol Phys 1983, 9:127-132.
16. Trott K, Kummermehr J: Rapid repopulation in radiotherapy: debate on mechanism, accelerated repopulation in tumor and normal tissue. Radiother Oncol 1991, 22:159-160.
17. Bourhis J, Dendale R, Hill C, Bosq J, Schwaab G, Armand JP, Wilbaut P, Luboinski B,. Malaise EP, Eschwege FG, et al.: Potential doubling time and clinical outcome in head and neck carcinoma treated with 70 Gy/7 weeks. Int J Radiat Oncol Biol Phys 1996, 33:1207-1211.
18. Begg A, Holfand I, van Glabekke M, Barteling H, Horiok JC: Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from EORTC cooperative trial 22551. Semin Radiat Oncol 1992, 2:22-25.
19. Wilson GD, McNally NJ, Dische S, Bennet M: Cell proliferation in human tumours measured by in vivo labelling with bromodeoxyuridine. Br J Cancer 1988, 58:423-431.
20. Bennet M, Wilson G, Dische S, Saunders M, Martindale C, O'Halloran A: Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 1992, 69:134-141
21. Fowler JF, Lindstrom M: Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992, 23:457-467.
22. Mendenhall W, Parson J, Milion R, Fletcher G: T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy relationship of dose-fractionation factors to local control and complications. Int J Radiat Oncol Biol Phys 1988, 15:1267-1273.
23. Overgaard J, Hjelm-Hansen M, Vendelbo J: Comparison of conventional and split-course as primary treatment in carcinoma of the larynx. Acta Oncologica 1988, 27:147-161.
24. Amdur R, Parson J, Mendenhall W, Million R, Cassini N: Split-course versus continuous-course irradiation in the postoperative setting for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1989, 17:279-285.
25. Taylor J, Withers H, Mendenhall W: Dose-time consideration of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 1990, 17:95-102.
26. Wang CC: Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys 1988, 14:1143-1146.
27. Knee R, Field R, Peters L, et al.: Concomitant boost radiotherapy for advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1985, 4:1-7.
28. Hahari P: Adding dose escalation to accelerated hyperfractionation for head and neck cancer, Semin Radiat Oncol 1992, 2:58-61.
29. Lusinchi A, Lartigau E, Luboinski B, Eschwege F: Accelerated radiotherapy in very advanced inoperable head and neck cancer. Int J Radiat Oncol Biol Phys 1994, 29:149-152.
30. Slevin N, Vasanthan S, Dougal M: Relative clinical influence of tumour dose versus dose per fraction on the occurrence of late normal tissue morbidity following larynx radiotherapy. Int J Radiat Oncol Biol Phys 1992, 25:1947-1951.
31. Bourhis J, Fortin A, Dupuis O, Lusinchi A, Mamelle G, Schwab G, Armand JP, Luboinski B, Malaise EP, Eschwege F, et al.: Very accelerated radiotherapy in locally unresectable head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1995, 32:747-752. A pilot study of very accelerated radiotherapy showing that 62 Gy given in 3 weeks was feasible, pending severe but manageable acute mucositis. This regimen is evaluated in a multicentric randomized trial against conventional radiation therapy.
32. Dische S, Saunders M: Continuous hyperfractionated accelerated radiotherapy (CHART): an interim report upon late morbidity. Radiother Oncol 1989, 16:67-74.
33. Saunders M, Dische S, Barrett A, et al.: Randomized multicentre trial of CHART vs conventional radiotherapy in head and neck and non small cell lung cancer: an interim report. Br J Cancer 1996, 73:1455-1462. Preliminary results of a large British randomized trial that included more than 900 HNSCC patients treated either with continuous hyperfractionated accelerated radiotherapy trial (54 Gy in 12 days) or with 66 Gy in 6.6 weeks. Subgroup analysis showed an improved local-regional control rate in T3-4 and also in larynx carcinoma in favor of the accelerated arm.
34. Dobrowsky W, Dobrowsky E, Naudė J, et al.: Conventional versus accelerated in advanced head and neck cancer. Br J Cancer 1996, (suppl)74:279-281. An interim report of a randomized trial from Austria comparing 55 Gy for 3 weeks with or without mitomycin to conventional radiation therapy alone.
35. Lamb D, Spry N, Gray A, et al.: Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother Oncol 1990, 18:107-116.
36. Nguyen T, Demange L, Froissard D, et al.: Rapid hyperfractionated radiotherapy: clinical results in 178 advanced squamous cell carcinomas of the head and neck. Cancer 1985, 56:16-19.
37. Perrachia G, Salti C: Radiotherapy with 3 fractions/day in a short overall time, clinical experience. Int J Radiat Oncol Biol Phys 1981, 7:99-104.
38. Olmi P: Very accelerated radiotherapy in advanced head and neck carcinomas. Radiother Oncol 1992, 34:109-113.
39. Svoboda V: Accelerated fractionation: the portsmounth experience. Proceedings of the Varian's 4th European Meeting 1984:70-75.
40. Fu K, Cooper J, Marcial V, et al.: Evolution of the radiation therapy oncology group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 1996, 35:425-438.
41. Ang K, Trotti A, Garden A, Foote R, Morrison W, Geare F, Klotch D, Goefert H, Peters L: Importance of overall time factor in post-operative radiotherapy. Proceedings of the 4th International Conference on Head and Neck Cancer 1996:231-235. The only randomized trial comparing accelerated radiotherapy to conventional radiotherapy in patients treated with postoperative radiotherapy. This study demonstrated the importance of cumulative time factors in determining locoregional control achievable with surgery plus radiation in patients with a risk of relapse. There was also a trend in favor of higher locoregional control rate with accelerated fractionation.
42. Cosset JM, Henry-Amar M, Girinski T, Malaise E, Dupouy N, Dutreix J: Late toxicity of radiotherapy in Hodgkin's disease: the role of fraction size. Acta Radiologica 1988, 27:123-129.
43. Dische S, Martin WM, Anderson P: Radiation myelopathy in patients treated for carcinoma of bronchus using a 6 fraction regimen of radiotherapy. Br J Radiol 1981, 54:29-35.
44. Fletcher GH: Hypofractionation: lessons from complications. Radiother Oncol 1991, 20:10-15
45. Turesson J, Notter G: The influence of fraction size in radiotherapy in the late normal tissue reactions: comparison of the effects of daily and once a week fractionation on human skin. Int J Radiat Oncol Biol Phys 1984, 10:593-598.
46. Bourhis J, Wilbaut P. Eschwege F: How worthwhile are accelerated radiation schedules? Int J Radiat Oncol Biol Phys 1995, 32:889-890.
47. Horiot JC, Bontemps P, Begg AC, Le Fur R, Van den Bogaert W, Bolea M, N'Guyen D, van den Weigngaert D, Bernier F, et al.: Radiothérapie hyperfractionnée et accélérée dans les cencers de la tête et du cou: résultats des essais EORTC et impact sur la pratique clinique. Bull Cancer Radiother 1996, 83:314-320. Preliminary results (in French) of a large EORTC (No22851) randomized trial that included more than 500 HNSCC patients treated either with accelerated radiotherapy (72 Gy in 5.5 weeks) or with conventional (70 Gy in 7 weeks), The analysis showed an improvement in the local-regional control, disease-free survival (LCR, DFS) (P < 0.01) and also in overall survival of borderline significance (P = 0.07) in favor of the accelerated arm. Increased late effect was also evident, suggesting that an interval between fraction of 4 hours might have been too short, given the relatively high dose per fraction used ( 1.6 Gy × 3 times daily) to allow optimal DNA repair in normal tissues.
48. Johnson C, Schmidt-Ullrich R, Douglas W: Standard once daily versus thrice-daily concomitant superfractionated irradiation for advanced carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1995, 32:162. An interim report of a randomized trial which included a limited number of patients and compared hyperfractionated accelerated radiation therapy with conventional radiation therapy, and showed a benefit in favor of the accelerated arm.
49. Jackson S, Weir L, Hay J, Tsang V, Durham S: A randomized trial of accelerated vs conventional radiotherapy in head and neck cancer. Proceedings of the 4th International Conference on Head and Neck Cancer 1996:53. A randomized trial comparing 66 Gy in 6.5 weeks to 66 Gy in 3.5 weeks that was stopped after inclusion of 82 patients because of increased grade IV late toxicity in the accelerated arm. No difference was seen in tumor control.
50. Munro AJ: An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995, 71:83-91. Meta-analysis based on 54 randomized trials comparing locoregional treatment alone versus the same treatment combined with chemotherapy. The analysis suggested no benefit for the use of neoadjuvant chemotherapy; however. it showed a significant improvement in survival in favor of the use of concomitant radiochemotherapy.